On August 7, 2019 Orion Corporation reported that sales of Nubeqa (darolutamide), jointly developed by Orion Corporation and Bayer for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC), has started in the USA. In connection with the successful commercialization of darolutamide in the USA, Orion receives from Bayer a EUR 45 million milestone (Press release, Orion , AUG 7, 2019, View Source [SID1234538321]). Orion will book the milestone in its third quarter 2019 result. The booking has no impact on Orion’s outlook for 2019 as the EUR 45 million milestone has been included in the financial guidance provided by the company.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Darolutamide is currently not approved by the European Medicines Agency or any other health authority outside the USA.

Contact person:
Tuukka Hirvonen, Investor Relations and Financial Communications, Orion Corporation
tel. +358 010 426 2721

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
www.orion.fi